Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Division of Hematology, Washington University School of Medicine, Saint Louis, Missouri, USA.
J Thromb Haemost. 2022 Dec;20(12):3026-3038. doi: 10.1111/jth.15896. Epub 2022 Oct 10.
Patients with cancer have an increased risk of thrombosis requiring anticoagulants and/or antiplatelet agents, and they can also encounter thrombocytopenia due to cancer itself or cancer therapies. They often undergo many procedures such as tissue or bone marrow biopsies, placement of central access lines, diagnostic or therapeutic draining procedures, lumbar puncture, and more. Management of antithrombotic agents or thrombocytopenia around the time of these procedures is highly variable. In this document, the Hemostasis and Malignancy Subcommittee of the International Society on Thrombosis and Haemostasis aims to provide useful practice guidance in the management of antithrombotic agents and thrombocytopenia around the time of common procedures in patients with cancer.
癌症患者发生血栓形成需要抗凝和/或抗血小板治疗的风险增加，并且由于癌症本身或癌症治疗，他们还可能会出现血小板减少症。他们经常接受许多操作，例如组织或骨髓活检、中央通道线的放置、诊断或治疗引流程序、腰椎穿刺等。这些操作时抗血栓药物或血小板减少症的管理具有高度的可变性。在本文件中，国际血栓止血学会止血和恶性肿瘤小组委员会旨在为癌症患者常见操作时抗血栓药物和血小板减少症的管理提供有用的实践指导。
